You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • EP404/#379  Discrepancies between patient and healthcare professional values in managing side effects of gynecologic anticancer drug therapy in Japan

Article Text

Article menu

Download PDFPDF

ePoster Viewing
AS20. Symptom management/supportive cancer care
EP404/#379  Discrepancies between patient and healthcare professional values in managing side effects of gynecologic anticancer drug therapy in Japan
Free
  1. Masakazu Abe1,
  2. Hironobu Hashimoto2,
  3. Azusa Soejima3,
  4. Yumiko Nishimura4,
  5. Ami Ike5,
  6. Michiko Sugawara5 and
  7. Muneaki Shimada6
  1. 1Hamamatsu University School of Medicine, Department of Obstetrics and Gynecology, Hamamatsu-shi, Japan
  2. 2National Cancer Center Hospital, Department of Pharmacy, Chuo-ku, Japan
  3. 3Cancer Institute Hospital, Japanese Foundation for Cancer Research, Department of Pharmacy, Ariake, Japan
  4. 4The Hospital of Hyogo College of Medicine, Department of Nursing, Nishinomiya-shi, Japan
  5. 5Eisai Co., Ltd, Medical Hqs, Bunkyo-ku, Japan
  6. 6Tohoku University Graduate School of Medicine, Department of Obstetrics and Gynecology, Sendai-shi, Japan

Abstract

Introduction It has been reported that physicians tend to underestimate the impact of side effects on their patients. It is important to understand patients‘ thoughts and values about side effects to provide a patient-centered treatment approach.

Methods A cross-sectional observational study (web-based questionnaire) was conducted among patients who had received anticancer drug therapy for uterine and ovarian cancer and heath care professionals (HCPs), including physicians, nurses, and pharmacists involved in gynecologic cancer care.

Results A survey was performed from November to December 2022, and responses were received from 154 patients, 153 physicians, 166 nurses, and 154 pharmacists. Regarding the differences in anticancer drug preferences, HCPs emphasized OS prolongation and tumor reduction, while patients emphasized safety (fewer side effects affecting activity and appearance) and complete elimination of cancer, with a significant difference between patients and physicians, especially in safety (figure 1). Regarding the extent of reporting of side effects, 49.4% of patients reported all symptoms, including adverse events and side effects, while 54.2% of physicians, 92.2% of nurses, and 85.7% of pharmacists wanted patients to report all symptoms including adverse events and side effects (figure 2).

Conclusion/Implications Anticancer drugs must be decided after understanding the patient‘s preferences through Shared Decision Making. It is important that not only physicians, but also nurses, pharmacists, and other members of the multi-disciplinary team listen to the patient-reported side effects/adverse events and provide support with respect to the patient‘s values, leading to appropriate management of side effects.

Abstract EP404/#379 Figure 1
Abstract EP404/#379 Figure 1

Differences in treatment preferences between patients and HCPs. The difference was calculated by subtracting the percentage (sum of top 3) of each HCP from that of patients (patients: n = 154, physicians: n = 154, nurses: n = 166, pharmacists: n = 154). *p<0.05, **p<0.01 by Fisher’s exact test. Questionnaire for HCPs: what are the top 3 that HCPs believe patients‘ value?, Questionnaire for patients: what are the top 3 do you think value most?

Abstract EP404/#379 Figure 2
Abstract EP404/#379 Figure 2

Comparison of the levels of communication about symptoms of side effects between patients and health care professionals

https://doi.org/10.1136/ijgc-2023-IGCS.449

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.